RESOMER RG 502 H is a bioresorbable 50:50 poly(D,L-lactide-co-glycolide) with acid termination and a low inherent viscosity specified on supplier certificates at 0.16–0.24 dL/g in 0.1% chloroform at 25 °C. The glass transition temperature is typically reported between 38 °C and 45 °C; the copolymer is amorphous and remains soluble in dichloromethane, acetone, ethyl acetate, dimethyl sulfoxide, and N-methyl-2-pyrrolidone under ambient conditions. Because the grade is designated as drug delivery material, batch release documentation includes residual D,L-lactide and glycolide monomers, residual solvents, catalyst residues such as tin, and heavy metals, with data supplied under current good manufacturing practice. The material is not supplied sterile and is not intended for direct clinical use without further processing.

Microsphere Fabrication via Double Emulsion Solvent Evaporation

Polymer solutions in dichloromethane at 5–20 wt% are prepared in jacketed reactors under nitrogen and filtered through 0.2 µm hydrophobic membranes. The drug phase is emulsified into the polymer-dichloromethane solution at aqueous-to-organic ratios between 1:5 and 1:20 using a rotor-stator disperser. The resultant primary emulsion is transferred into aqueous poly(vinyl alcohol) with a continuous-phase concentration of 0.5–2.0% w/v; the PVA degree of hydrolysis and molecular weight alter interfacial tension and must be controlled batchwise because the same rotor speed can shift median particle size by several microns. Hardening is carried out by controlled solvent extraction at 35–40 °C under reduced pressure for 2–6 h, after which microspheres are wet-sieved, washed, and lyophilized. Particle size is measured by laser diffraction in water with an obscuration range of 10–20% according to ISO 13320:2020, and residual moisture is determined by Karl Fischer titration per USP <921>. The accepted residual dichloromethane limit for parenteral microspheres is 600 ppm under ICH Q3C Option 2; residual PVA must be quantified and justified because no universal pharmacopoeial limit applies.

Release kinetics from RG 502 H microspheres are governed by PLGA molecular weight, particle size, drug loading, and continuous-phase processing. The acid terminal group increases water uptake and accelerates ester hydrolysis relative to ester-capped 50:50 PLGA of equivalent inherent viscosity. In vitro release in phosphate-buffered saline at 37 °C and sink conditions frequently exhibits a burst of 5–25% of the loaded drug within 24 h, followed by a diffusion-controlled phase and a final erosion-controlled phase; however, published data for this specific configuration is limited. Release testing is performed with USP Apparatus 2 or 4 at 50–100 rpm and 37 °C, with sampling through low-binding filters. Microsphere formulations intended for once-monthly depot injection require a reproducible outer porous layer and a mean particle size above 20 µm to reduce phagocyte-mediated clearance, while sub-10 µm particles are removed more quickly and increase systemic exposure. Each batch must be characterized for glass transition by differential scanning calorimetry at 10 °C/min according to ASTM E1356 after lyophilization because residual solvent plasticization lowers the measured Tg.

For nanoprecipitation and subsequent lyophilization, RESOMER RG 502 H is dissolved at 10–25 mg/mL in acetone or acetonitrile and injected through a 20–28 gauge needle into an aqueous stabilizer phase containing poloxamer 188 or polysorbate 80 at 0.1–0.5% w/v under magnetic or high-shear stirring. Nanoprecipitation produces particles with Z-average diameters of 80–200 nm and polydispersity indices below 0.2 when the solvent-to-nonsolvent ratio exceeds 1:10 and the organic phase is introduced rapidly. Dynamic light scattering per ISO 22412:2017 reports intensity-weighted size; lyophilization requires cryoprotectant addition at 5–10% w/v trehalose or sucrose to prevent aggregation. Residual acetone and acetonitrile are Class 3 solvents with ICH Q3C limits of 5000 ppm and 410 ppm, respectively. The low molecular weight of RG 502 H reduces organic-solvent viscosity, but drug-polymer phase separation during solvent diffusion can reduce encapsulation efficiency below 30% for crystalline APIs with log P above 4. Aqueous-phase pH adjustment with dilute hydrochloric acid or sodium hydroxide is used when the API exhibits pH-dependent solubility. Terminal sterile filtration through 0.22 µm membranes is only feasible for particles below 100 nm; larger particles require aseptic processing.

What Determines Syringeability in NMP-Based In-Situ Forming Implants?

Syringeability of solutions of RG 502 H in N-methyl-2-pyrrolidone is governed by polymer concentration, solution temperature, needle gauge, and injection rate. At polymer loadings of 20–40 wt%, viscosity measured by cone-plate rheometry at 10 s−1 and 25 °C per ISO 3219-1:2021 remains below 2 Pa·s, allowing manual injection through 21–23 G needles. When dimethyl sulfoxide is substituted for NMP, the solution may exhibit lower viscosity but faster solvent exchange with surrounding water, leading to rapid liquid-liquid demixing and a less uniform depot. The acid-terminal groups of RG 502 H reduce solution stability in the presence of trace water; polymer solutions are therefore prepared under dry nitrogen and stored in glass syringes with low moisture vapor transmission.

Upon subcutaneous or intramuscular injection, NMP concentration at the depot boundary decreases below the critical concentration for polymer precipitation, and a gel shell forms within 30–120 s; final depot geometry depends on injection volume and tissue back pressure. Release from these depots is controlled first by solvent extraction and later by bulk erosion. For a low-molecular-weight acid-terminated 50:50 PLGA, degradation within an aqueous environment is measurable by gel-permeation chromatography within 7–14 days, but published data for this specific formulation is limited. Residual NMP in a parenteral product is classified as a Class 2 solvent with an ICH Q3C limit of 530 ppm; however, depot products are evaluated based on total administered solvent and the elution profile at the injection site. Terminal sterilization of in-situ forming implants is limited to aseptic manufacturing in most cases; gamma irradiation at 25 kGy reduces molecular weight and changes syringeability due to chain scission.

Electrospinning of RG 502 H as the sole polymer is constrained by the low molecular weight of the grade. Solutions at 15–30 wt% in chloroform-dimethylformamide or hexafluoroisopropanol often require blending with a higher-inherent-viscosity PLGA or polycaprolactone at 20–50 wt% of total polymer to stabilize the jet and reduce bead defects. Fibers collected at 15–25 kV on a rotating mandrel show diameters of 400–1200 nm by scanning electron microscopy; the presence of acid-terminal end groups accelerates fiber hydration and mechanical relaxation in phosphate-buffered saline at 37 °C. Residual dimethylformamide must be reduced below 880 ppm under ICH Q3C; vacuum drying below 50 °C is necessary to avoid thermal degradation. Electrospun constructs containing RG 502 H lose tensile strength and break elongation after 7–14 days in aqueous media, but published data for this specific configuration is limited. This route is more relevant for topical or mucosal delivery where drug release occurs within days, not for long-term load-bearing scaffolds.

Hot-Melt Extrusion Without Triggering Hydrolytic Degradation Above the 130°C Threshold

Compounding of RG 502 H by twin-screw extrusion is carried out with a barrel configuration of 20:1–40:1 L/D ratio and temperature zones set between 90 °C and 120 °C. The low melt viscosity produces torque below 15 N·m at screw speeds of 50–200 rpm, but the processing window narrows sharply above 130 °C. At that threshold, hydrolytic and thermal backbone scission occurs, and measurable reduction in molecular weight by gel-permeation chromatography can be detected after 5–10 min residence time. Feedstock must be dried under vacuum at 40–50 °C for 24–48 h to a moisture content below 0.5%, because the acid terminal groups catalyze hydrolysis in the presence of residual water. API loadings of 10–30 wt% are processed; amorphous drug recrystallization during storage is a known failure mode when drug-polymer miscibility is exceeded, and physical stability is assessed by differential scanning calorimetry with a heating rate of 10 °C/min.

Extrudate from RG 502 H can be pelletized and injection molded into solid implants at barrel temperatures of 100–120 °C and mold temperatures of 20–25 °C; cold mold surfaces reduce dimensional distortion but may induce orientation. The molded implants are tested for molecular weight retention by gel-permeation chromatography; a reduction above 10% relative to unprocessed polymer generally indicates thermal degradation or inadequate drying. Sterilization of extruded implants by gamma irradiation at 25 kGy is common for implantable devices but requires post-irradiation gel-permeation chromatography and dissolution testing because chain scission reduces Tg and alters release. Ethylene oxide is generally not recommended for low-Tg PLGA because gas absorption and residual ethylene oxide and chlorohydrin limits create additional analytical burden.

When Residual Monomer Content Drives Release-Lag in Ocular Depot Injection

Ophthalmic depot products formulated with RG 502 H must address residual monomer and oligomer levels more tightly than non-ocular parenterals. D,L-lactide and glycolide monomers are quantified by gas chromatography from supplier certificates, typically reported as weight percent relative to polymer. Residual monomer accelerates acidification and water uptake in the vitreous cavity; local pH excursions can contribute to vitreous opacity or cellular toxicity. Finished product testing includes ophthalmic particulate limits per USP <789> and visible particulate inspection per USP <790>, with rejection of aggregates above 100 µm. In vitro release in simulated vitreous humor at 37 °C often shows an initial hydration lag during the first 24–72 h, followed by diffusion and erosion phases; published data for this specific configuration is limited.

Particle size measurement by laser diffraction per ISO 13320:2020 is combined with pH monitoring of release media; a pH drop below 6.5 is undesirable for ocular formulations. Cytotoxicity evaluation per ISO 10993-5 and extractables profiling per ISO 10993-12 are used to assess polymer impurities, including tin residues and residual monomers. Terminal sterilization by gamma irradiation is possible at 15–25 kGy, but molecular weight distribution must be verified before release. Aseptic manufacturing is the primary route when particle suspensions or in-situ depots are filled into prefilled syringes.

Spray coating of metallic or polymeric implant surfaces uses RG 502 H at 1–5 wt% in dichloromethane or ethyl acetate, applied with ultrasonic atomization. Coating thicknesses of 2–20 µm are measured by step profilometry or scanning electron microscopy cross-section; the low glass transition of 38–45 °C necessitates low-temperature drying below 50 °C. Adhesion failure occurs on cobalt-chromium alloy surfaces unless a silane or plasma treatment is used. Residual dichloromethane in the finished device must be below 600 ppm; extractables profiling according to ISO 10993-12 is required. Simulated deployment testing includes light microscopy after crimping or balloon expansion, and particulates in rinse solutions are counted per USP <788>. Gamma irradiation at 25 kGy is used for device sterilization; however, molecular weight reduction and coating-brittleness changes must be assessed, and published data for this specific configuration is limited.